Experienced in Isolated Hypogonadotropic Hypogonadism

Dr. David Fitz

Endocrinology
David Fitz-Patrick, MD Inc.
1585 Kapiolani Blvd, Suite 1500, 
Honolulu, HI 
Experienced in Isolated Hypogonadotropic Hypogonadism
David Fitz-Patrick, MD Inc.
1585 Kapiolani Blvd, Suite 1500, 
Honolulu, HI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Fitz is an Endocrinologist in Honolulu, Hawaii. Dr. Fitz is rated as an Experienced provider by MediFind in the treatment of Isolated Hypogonadotropic Hypogonadism. His top areas of expertise are Type 2 Diabetes (T2D), Prolactinoma, Pituitary Tumor, and Obesity in Children.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Endocrinology
Licenses
Specialist in HI
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AlohaCare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Hawaii Medical Assurance Association
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PacificSource
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

DAVID FITZ-PATRICK, MD INC.
1585 Kapiolani Blvd, Suite 1500, Honolulu, HI 96814

Additional Areas of Focus

Dr. Fitz has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Hypoparathyroidism
Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Other
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Enrollment Status: Completed
Publish Date: May 22, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
An Assessment of the Impact of an App Based Diabetes Training Program in Conjunction With the Use of BD Nano 2nd Gen 4mm Pen Needle on Diabetes Self-efficacy in People With Type 2 Diabetes
An Assessment of the Impact of an App Based Diabetes Training Program in Conjunction With the Use of BD Nano 2nd Gen 4mm Pen Needle on Diabetes Self-efficacy in People With Type 2 Diabetes
Enrollment Status: Terminated
Publish Date: July 08, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Enrollment Status: Completed
Publish Date: March 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)
A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: January 05, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: June 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs the Artsana Insupen® Extr3me 4mm x 33G, Artsana Insupen® Extr3me 3.5mm x 34G and the Simple Diagnostics Comfort EZ™ 4mm x 33G Pen Needles
Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs the Artsana Insupen® Extr3me 4mm x 33G, Artsana Insupen® Extr3me 3.5mm x 34G and the Simple Diagnostics Comfort EZ™ 4mm x 33G Pen Needles
Enrollment Status: Completed
Publish Date: March 09, 2020
Intervention Type: Device
Study Phase: Not Applicable
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

13 Total Publications

Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trial.
Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trial.
Journal: Respiratory investigation
Published: March 06, 2024
Similar Doctors
Advanced in Isolated Hypogonadotropic Hypogonadism
Dr. Frank D. Singer
Endocrinology
Advanced in Isolated Hypogonadotropic Hypogonadism
Dr. Frank D. Singer
Endocrinology

Straub Clinic And Hospital

98 -1079 Moanalua Rd, 
Aiea, HI 
 (9.0 miles away)
808-486-6000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Frank Singer is an Endocrinologist in Aiea, Hawaii. Dr. Singer is rated as an Advanced provider by MediFind in the treatment of Isolated Hypogonadotropic Hypogonadism. His top areas of expertise are Postmenopausal Osteoporosis, Osteoporosis, Type 2 Diabetes (T2D), and Graves Disease.

Experienced in Isolated Hypogonadotropic Hypogonadism
Dr. Sheri Y. Chinen
Endocrinology
Experienced in Isolated Hypogonadotropic Hypogonadism
Dr. Sheri Y. Chinen
Endocrinology

Straub Clinic And Hospital

888 S King St, Suite 700, 
Honolulu, HI 
 (1.1 miles away)
808-522-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sheri Chinen is an Endocrinologist in Honolulu, Hawaii. Dr. Chinen is rated as a Distinguished provider by MediFind in the treatment of Isolated Hypogonadotropic Hypogonadism. Her top areas of expertise are Graves Disease, Thyroid Storm, Hyperparathyroidism, and Parathyroid Hyperplasia.

Experienced in Isolated Hypogonadotropic Hypogonadism
Dr. John H. Meyer
Endocrinology
Experienced in Isolated Hypogonadotropic Hypogonadism
Dr. John H. Meyer
Endocrinology
1329 Lusitana St, Suite 705, 
Honolulu, HI 
 (1.3 miles away)
808-524-0400
Languages Spoken:
English
See accepted insurances

John Meyer is an Endocrinologist in Honolulu, Hawaii. Dr. Meyer is rated as an Advanced provider by MediFind in the treatment of Isolated Hypogonadotropic Hypogonadism. His top areas of expertise are Thyroid Cancer, Follicular Thyroid Cancer, Anaplastic Thyroid Cancer, and Papillary Thyroid Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fitz's expertise for a condition
ConditionClose
      View All 38 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile